Trial reportGut2017
Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.
Trial report in Gut, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00468910 (Spectral Markers in Aspirin Chemoprevention of Colonic Neoplasia), which is not on this map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Spectral Markers in Aspirin Chemoprevention of Colonic Neoplasia
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Aspirin use for cancer prevention: A systematic review of public, patient and healthcare provider attitudes and adherence behaviours.Preventive medicine · 2022Pooled it
- Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2016Pooled it
- Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial.PloS one · 2018Trial
- Trial
- Navigating the Colorectal Cancer Maze: Unveiling Pathways To Diagnosis, Management, Pathophysiology and Prevention.Current oncology reports · 2025Review
- Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes.Clinics in colon and rectal surgery · 2024Review
- Multiscale optical phase fluctuations link disorder strength and fractal dimension of cell structure.Biophysical journal · 2023Article
- ICOS/ICOSLG and PD-1 Co-Expression is Associated with the Progression of Colorectal Precancerous- Carcinoma Immune Microenvironment.Journal of inflammation research · 2023Article
- Mechanisms of Colorectal Cancer Prevention by Aspirin-A Literature Review and Perspective on the Role of COX-Dependent and -Independent Pathways.International journal of molecular sciences · 2020Review
- The molecular mechanisms of celecoxib in tumor development.Medicine · 2020Article
- Review
- Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction.JNCI cancer spectrum · 2020Article
- Article
- Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology.Annual review of pathology · 2019Review
- Elimination of CD4Cell research · 2018Article
- Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.Gut · 2018Review
- Correlating colorectal cancer risk with field carcinogenesis progression using partial wave spectroscopic microscopy.Cancer medicine · 2018Article
- Article
- Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology.NPJ precision oncology · 2017Article
- Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes.Gastroenterology · 2016Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 1 country.
Funding
Abstract
objectiveA major impediment to translating chemoprevention to clinical practice has been lack of intermediate biomarkers. We previously reported that rectal interrogation with low-coherence enhanced backscattering spectroscopy (LEBS) detected microarchitectural manifestations of field carcinogenesis. We now wanted to ascertain if reversion of two LEBS markers spectral slope (SPEC) and fractal dimension (FRAC) could serve as a marker for chemopreventive efficacy.
designWe conducted a multicentre, prospective, randomised, double-blind placebo-controlled, clinical trial in subjects with a history of colonic neoplasia who manifested altered SPEC/FRAC in histologically normal colonic mucosa. Subjects (n=79) were randomised to 325 mg aspirin or placebo. The primary endpoint changed in FRAC and SPEC spectral markers after 3 months. Mucosal levels of prostaglandin E2 (PGE2) and UDP-glucuronosyltransferase (UGT)1A6 genotypes were planned secondary endpoints.
resultsAt 3 months, the aspirin group manifested alterations in SPEC (48.9%, p=0.055) and FRAC (55.4%, p=0.200) with the direction towards non-neoplastic status. As a measure of aspirin's pharmacological efficacy, we assessed changes in rectal PGE2 levels and noted that it correlated with SPEC and FRAC alterations (R=-0.55, p=0.01 and R=0.57, p=0.009, respectively) whereas there was no significant correlation in placebo specimens. While UGT1A6 subgroup analysis did not achieve statistical significance, the changes in SPEC and FRAC to a less neoplastic direction occurred only in the variant consonant with epidemiological evidence of chemoprevention.
conclusionsWe provide the first proof of concept, albeit somewhat underpowered, that spectral markers reversion mirrors antineoplastic efficacy providing a potential modality for titration of agent type/dose to optimise chemopreventive strategies in clinical practice. TRIAL NUMBER: NCT00468910.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.